Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer’s Disease
Juan A. Sánchez‐Arias, Obdulia Rabal, Mar Cuadrado‐Tejedor, et al.
ACS Chemical Neuroscience (2016) Vol. 8, Iss. 3, pp. 638-661
Closed Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation
Surabhi Shukla, Babu L. Tekwani
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 220
Epigenetic polypharmacology: A new frontier for epi‐drug discovery
Daniela Tomaselli, Alessia Lucidi, Dante Rotili, et al.
Medicinal Research Reviews (2019) Vol. 40, Iss. 1, pp. 190-244
Open Access | Times Cited: 96
An outline for the pharmacological effect of icariin in the nervous system
Jie Jin, Hui Wang, Xiao‐Ying Hua, et al.
European Journal of Pharmacology (2018) Vol. 842, pp. 20-32
Closed Access | Times Cited: 95
GPR55: A therapeutic target for Parkinson's disease?
Marta Celorrio, Estefanía Rojo-Bustamante, Diana Fernández‐Suárez, et al.
Neuropharmacology (2017) Vol. 125, pp. 319-332
Closed Access | Times Cited: 93
Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives
Ahmed K. ElHady, Dalia S. El‐Gamil, Mohammad Abdel‐Halim, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 9, pp. 1266-1266
Open Access | Times Cited: 24
Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders
Rohan Gupta, Rashmi K. Ambasta, Pravir Kumar
Life Sciences (2020) Vol. 243, pp. 117278-117278
Closed Access | Times Cited: 66
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease
Obdulia Rabal, Juan A. Sánchez‐Arias, Mar Cuadrado‐Tejedor, et al.
European Journal of Medicinal Chemistry (2018) Vol. 150, pp. 506-524
Closed Access | Times Cited: 63
Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective
Yuan Gao, Hang Zhang, Frédéric Lirussi, et al.
Biochemical Pharmacology (2020) Vol. 182, pp. 114224-114224
Open Access | Times Cited: 60
Histone Deacetylase Inhibitors as Multitarget Ligands: New Players in Alzheimer's Disease Drug Discovery?
Angela De Simone, Andrea Milelli
ChemMedChem (2019) Vol. 14, Iss. 11, pp. 1067-1073
Closed Access | Times Cited: 58
Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities
Daniel A. Rodrigues, Pedro de Sena Murteira Pinheiro, Fernanda S. Sagrillo, et al.
Medicinal Research Reviews (2020) Vol. 40, Iss. 6, pp. 2177-2211
Closed Access | Times Cited: 56
β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer’s Disease Therapy
Aurélien Beato, Anthonin Gori, Benjamin Boucherle, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 3, pp. 1392-1422
Open Access | Times Cited: 55
A review of synthetic bioactive tetrahydro-β-carbolines: A medicinal chemistry perspective
Jiayun Wang, Feihu Gong, Ting Liang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 225, pp. 113815-113815
Closed Access | Times Cited: 45
Opportunities and perspectives of small molecular phosphodiesterase inhibitors in neurodegenerative diseases
Qi Li, Qinghong Liao, Shulei Qi, et al.
European Journal of Medicinal Chemistry (2024) Vol. 271, pp. 116386-116386
Closed Access | Times Cited: 7
Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer’s Disease
Fei Mao, Huan Wang, Wei Ni, et al.
ACS Chemical Neuroscience (2017) Vol. 9, Iss. 2, pp. 328-345
Closed Access | Times Cited: 60
Therapeutic Potential of Phosphodiesterase Inhibitors against Neurodegeneration: The Perspective of the Medicinal Chemist
Giovanni Ribaudo, Alberto Ongaro, Giuseppe Zagotto, et al.
ACS Chemical Neuroscience (2020) Vol. 11, Iss. 12, pp. 1726-1739
Open Access | Times Cited: 48
Innovative pathological network‐based multitarget approaches for Alzheimer's disease treatment
Paloma Mayo, Jorge Pascual-Guerra, Enrique Crisman, et al.
Medicinal Research Reviews (2024) Vol. 44, Iss. 6, pp. 2367-2419
Open Access | Times Cited: 5
Taking Advantage of the Selectivity of Histone Deacetylases and Phosphodiesterase Inhibitors to Design Better Therapeutic Strategies to Treat Alzheimer’s Disease
Mar Cuadrado‐Tejedor, Marta Pérez-González, Cristina García‐Muñoz, et al.
Frontiers in Aging Neuroscience (2019) Vol. 11
Open Access | Times Cited: 42
Paradigm shift of “classical” HDAC inhibitors to “hybrid” HDAC inhibitors in therapeutic interventions
Gargi Nikhil Vaidya, Pooja Rana, Ashwini Venkatesh, et al.
European Journal of Medicinal Chemistry (2020) Vol. 209, pp. 112844-112844
Closed Access | Times Cited: 33
Multitarget Approach for the Treatment of Alzheimer’s Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles
Obdulia Rabal, Juan A. Sánchez‐Arias, Mar Cuadrado‐Tejedor, et al.
ACS Chemical Neuroscience (2019) Vol. 10, Iss. 9, pp. 4076-4101
Closed Access | Times Cited: 35
Discovery of in Vivo Chemical Probes for Treating Alzheimer’s Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors
Obdulia Rabal, Juan A. Sánchez‐Arias, Mar Cuadrado‐Tejedor, et al.
ACS Chemical Neuroscience (2018) Vol. 10, Iss. 3, pp. 1765-1782
Closed Access | Times Cited: 34
Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer’s disease
Li Liu, Xu Huang, Shumin Ding, et al.
Brain Research Bulletin (2019) Vol. 153, pp. 223-231
Closed Access | Times Cited: 34
Tuning Properties for Blood–Brain Barrier Permeation: A Statistics-Based Analysis
Maria Dichiara, Benedetto Amata, Rita Turnaturi, et al.
ACS Chemical Neuroscience (2019) Vol. 11, Iss. 1, pp. 34-44
Closed Access | Times Cited: 30
Advances in the development of phosphodiesterase 5 inhibitors
Tieqiang Zong, Xing Huang, Wei Zhou, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117365-117365
Closed Access
Recent Advances in Catalytic Carbonylation Reactions in Alternative Reaction Media
Csaba Árvai, László T. Mika
Chinese Journal of Chemistry (2023) Vol. 42, Iss. 4, pp. 406-429
Open Access | Times Cited: 9
Novel Tadalafil Derivatives Ameliorates Scopolamine-Induced Cognitive Impairment in Mice via Inhibition of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5)
Wei Ni, Huan Wang, Xiaokang Li, et al.
ACS Chemical Neuroscience (2018) Vol. 9, Iss. 7, pp. 1625-1636
Closed Access | Times Cited: 25
Page 1 - Next Page

Scroll to top